Advanced

Serum proteome profiling of metastatic breast cancer using recombinant antibody microarrays.

Carlsson, Anders LU ; Wingren, Christer LU ; Ingvarsson, Johan LU ; Ellmark, Peter LU ; Baldetorp, Bo LU ; Fernö, Mårten LU ; Olsson, Håkan LU and Borrebaeck, Carl LU (2008) In European Journal of Cancer 44(3). p.472-480
Abstract
The driving force behind oncoproteomics is to identify biomarker signatures associated with a particular malignancy. Here, we have for the first time used large-scale recombinant scFv antibody microarrays in an attempt to classify metastatic breast cancer versus healthy controls, based on differential protein expression profiling of whole serum samples. Using this multiplexed and miniaturised assay set-up providing pM range sensitivities, breast cancer could be classified with a specificity and sensitivity of 85% based on 129 serum analytes. However, by adopting a condensed 11 analyte biomarker signature, composed of nine non-redundant serum proteins, we were able to distinguish cancer versus healthy serum proteomes with a 95% sensitivity... (More)
The driving force behind oncoproteomics is to identify biomarker signatures associated with a particular malignancy. Here, we have for the first time used large-scale recombinant scFv antibody microarrays in an attempt to classify metastatic breast cancer versus healthy controls, based on differential protein expression profiling of whole serum samples. Using this multiplexed and miniaturised assay set-up providing pM range sensitivities, breast cancer could be classified with a specificity and sensitivity of 85% based on 129 serum analytes. However, by adopting a condensed 11 analyte biomarker signature, composed of nine non-redundant serum proteins, we were able to distinguish cancer versus healthy serum proteomes with a 95% sensitivity and specificity, respectively. When a subgroup of patients, not receiving anti-inflammatory drugs, was analysed, a novel eight analyte biomarker signature with a further improved predictive power was indicated. In a longer perspective, antibody microarray analysis could provide a tool for the development of improved diagnostics and intensified biomarker discovery for breast cancer patients. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
European Journal of Cancer
volume
44
issue
3
pages
472 - 480
publisher
Elsevier
external identifiers
  • pmid:18171612
  • wos:000254027400024
  • scopus:38749122786
ISSN
1879-0852
DOI
10.1016/j.ejca.2007.11.025
project
CREATE Health
language
English
LU publication?
yes
id
93668718-b5d0-4e18-8811-7fc2c4f1bf6e (old id 1021672)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/18171612?dopt=Abstract
date added to LUP
2008-02-08 14:29:46
date last changed
2017-07-09 03:48:24
@article{93668718-b5d0-4e18-8811-7fc2c4f1bf6e,
  abstract     = {The driving force behind oncoproteomics is to identify biomarker signatures associated with a particular malignancy. Here, we have for the first time used large-scale recombinant scFv antibody microarrays in an attempt to classify metastatic breast cancer versus healthy controls, based on differential protein expression profiling of whole serum samples. Using this multiplexed and miniaturised assay set-up providing pM range sensitivities, breast cancer could be classified with a specificity and sensitivity of 85% based on 129 serum analytes. However, by adopting a condensed 11 analyte biomarker signature, composed of nine non-redundant serum proteins, we were able to distinguish cancer versus healthy serum proteomes with a 95% sensitivity and specificity, respectively. When a subgroup of patients, not receiving anti-inflammatory drugs, was analysed, a novel eight analyte biomarker signature with a further improved predictive power was indicated. In a longer perspective, antibody microarray analysis could provide a tool for the development of improved diagnostics and intensified biomarker discovery for breast cancer patients.},
  author       = {Carlsson, Anders and Wingren, Christer and Ingvarsson, Johan and Ellmark, Peter and Baldetorp, Bo and Fernö, Mårten and Olsson, Håkan and Borrebaeck, Carl},
  issn         = {1879-0852},
  language     = {eng},
  number       = {3},
  pages        = {472--480},
  publisher    = {Elsevier},
  series       = {European Journal of Cancer},
  title        = {Serum proteome profiling of metastatic breast cancer using recombinant antibody microarrays.},
  url          = {http://dx.doi.org/10.1016/j.ejca.2007.11.025},
  volume       = {44},
  year         = {2008},
}